pHion Therapeutics

pHion Therapeutics, a UK-based biotech startup, focuses on developing groundbreaking nucleic acid vaccines and therapeutics, with a proprietary RALA peptide-based drug delivery system. This system has the ability to condense anionic cargo into nanoparticles, allowing for highly efficient cellular entry and a 100% release rate from endosomes. The RALA platform is capable of delivering multiple anionic molecules, such as mRNA, in a stealth-like manner, generating a potent antigen-specific CD8+ T-cell response ideal for therapeutic vaccines and long-term T-cell and antibody memory ideal for prophylactic vaccines. Moreover, the platform offers scalability, sustainability, and reduced wastage in product formulation. pHion’s lead product, a therapeutic vaccine against HPV driven cancers (PTX_V1), is set to commence Phase I/IIA clinical trials in 2024. The startup's pipeline programs include therapeutic vaccines against ovarian cancer (PTX_V5), prostate cancer (PTX_V3), and a prophylactic vaccine against Crimean-Congo Haemorrhagic Fever. invoX Pharma, an integrated global biopharmaceutical company, is the majority shareholder of pHion Therapeutics. Founded in 2017, the company is headquartered in Belfast, Northern Ireland. The latest financial injection, a Corporate Round investment, was received on 01 June 2023 from invoX Pharma. To learn more about invoX, visit: www.invoxpharma.com.